Greenlee Pharmaceuticals and AstraZeneta are once again strategically working together to actively advance the cardiovascular and oncology sectors...

On December 28, 2020, Greenleaf Pharmaceutical Group and AstraZeneca signed a Memorandum of Strategic Cooperation, which will actively explore in-depth cooperation in the field of cardiovascular and oncology, focusing on green leaf pharmaceutical's natural drug hemolipid congen ®capsulates, in the field of oncology, innovative agent lipotin® and the anti-tumor biopharmaceutical beva bead monoantigen (LY01008) developed by Shandong Boan Biotechnology Co., Ltd., a subsidiary of Greenleaf Pharmaceuticals.
Signing Ceremony Left: Green Leaf Pharmaceutical Group Vice President Jiang Hua right: AstraZeneta China Strategic Cooperation and Business Development Vice President Chen Bing blood lipid kang ®, Lipporin ®, Beval pearl single anti-injection (LY01008) is Green leaf pharmaceutical in the field of cardiovascular and oncology independent research and development of the core products / products in research.
of these, hemolipid ® is a natural lipid-adjusted drug and has completed the U.S. Food and Drug Administration (FDA) Phase II clinical study.
is a ® lipolytic agent used to treat breast, non-small cell lung and ovarian cancer.
Beval bead single anti-injection (LY01008) is used to treat advanced, metastatic or reocculative non-small cell lung cancer and metastatic colorectal cancer, and the product was declared for listing in China in April 2020.
the strategic cooperation memorandum, Greenlee Pharmaceuticals and AstraZeneta will actively explore the direction of future cooperation on the basis of existing cooperation, hoping to further enhance the depth and breadth of cooperation.
In the cardiovascular field, the two sides will explore more innovative promotion models around Internet medical and online channels based on the existing global commercial cooperation to further improve the access of patients with lipid kang ® capsules.
In the field of oncology, the two sides will explore how to jointly develop their respective strengths to further deepen the coverage of the force® in a wide area and market segment, and will strengthen communication on opportunities for cooperation in clinical academic research in the product's follow-up.
In addition, the two sides will conduct in-depth research on LY01008, another large tumor in green leaf pharmaceutical research products, and AstraZenecon anti-tumor drugs, and actively explore LY01008 cooperation space in major international emerging markets outside China.
。